Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 196

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 8
Chunk 196
---
,
the Company issued 173 shares of Common Stock to Arena valued at $500,000, which is reflected as deferred offering costs on the accompanying
consolidated balance sheet as of December 31, 2024. The Company has sold no shares of Common Stock to Arena under the Arena ELOC during
the nine months ended September 30, 2025 and 2024. As of September 30, 2025, the Company wrote off the deferred offering costs of $500,000
since the likelihood of raising funds pursuant to the Arena Purchase Agreement is unlikely. Accordingly, during the three and nine months
ended September 30, 2025, the Company recorded a write off of deferred offering costs of $500,000, which is reflected in other income
(expenses) on the accompanying unaudited condensed statements of operations.

Sale of Pre-funded Warrants and Common Stock

On February 5, 2025, the
Company announced the pricing of a reasonable best efforts public offering (the “Offering”), with participation from a member
of the Company’s board of directors and a single institutional investor, for the purchase and sale of (i) 127,551 shares of Common
Stock or common stock equivalents in lieu thereof (the Company sold 15,000 shares of its common stock and 112,551 pre-funded warrants);
and (ii) common warrants to purchase up to 127,551 shares of common stock (the “Warrants”), at a combined public offering
price of $39.20 per share and Warrant. In connection with the Offering, on February 5, 2025, the Company entered into a securities purchase
agreement (the “SPA”) with the investors. The SPA contains customary representations, warranties and agreements of the Company
and each investor and customary indemnification rights and obligations of the parties. In connection with this offering, the Company received
net proceeds of approximately $4.2 million, which is net of offering costs and fees of $839,004. During the three months ended March 31,
2025, 15,000 shares of common stock were purchased upon the closing of the Offering and 91,214 shares were issued in connection with the
exercise of pre-funded warrants, totaling 106,214 shares of its common stock issued of the aggregate amount of 127,551 Common Stock shares
sold. During the three months ended June 30, 2025, 10,550 shares were issued in connection with the exercise